HALO Insider Mahesh Krishnan Sells $548K of Stock
Mahesh Krishnan sold over 7,300 shares of Halozyme Therapeutics, valued at approximately $547,800.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics, Inc. ($HALO) at an average price of $75, worth about $547,800, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $HALO is up 4.7% after 1 week, up 7.9% after 1 month and up 57.9% to date (from the $77.18 close on Jun 29, 2026).
HALO
Halozyme Therapeutics, Inc.
Key Points
- Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics for about $547,800 on June 29, 2026.
- Halozyme's stock closed at $78.27 on Wednesday, which is significantly below its 52-week high of $113.47.
- Analysts maintain a consensus 'Buy' rating for Halozyme, with a mean price target of $99.56.
Get $HALO trade alerts by text
We text you when insiders, Congress or big funds trade $HALO. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Halozyme Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Halozyme Therapeutics, Inc.
Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics (NASDAQ: HALO) on June 29, 2026, for about $547,800, at a price of $75 per share. This planned sale comes just after Krishnan had previously purchased the same number of shares on the same day.
Analysts Set New Price Targets
Analysts continue to have a positive outlook on Halozyme. On October 13, 2026, TD Cowen maintained a 'Buy' rating and raised its price target to $130. JP Morgan also maintained a 'Neutral' rating with a target of $78 on October 8, 2026. HC Wainwright & Co. has been bullish, reiterating a 'Buy' rating and increasing its target from $115 to $130 on October 8, 2026. The stock’s current environment appears favorable with analysts showing confidence in its growth potential.
Stock Performance Context
Halozyme's shares traded at $78.27 on the day this article was published. The stock has seen notable volatility, with a 52-week range from $61.23 to $113.47. This recent insider sale happened at a time when the stock is currently trading lower than its recent highs, possibly reflecting broader market conditions or company-specific factors.
What Halozyme Therapeutics, Inc. Does
Halozyme Therapeutics, based in San Diego, CA, is a biopharmaceutical company that develops innovative enzyme-based therapies for delivering injectable biologics. With a strong market position in the biotechnology sector, the company’s proprietary technologies are critical for enhancing drug delivery.
Upcoming Earnings
Halozyme is scheduled to report its next earnings on November 2, 2026. Investors will be looking for updates on revenue and growth as the company continues to expand its market presence. The recent insider activities and analyst ratings will likely be a point of interest as these events unfold.
Related Filing Alerts
Source: Mahesh Krishnan's Form 4 filing on $HALO (Jun 29, 2026). Find the original filing: HALO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts